Kura Oncology Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Kura Oncology Inc (KURA)
Kura Oncology Inc stock price live, this page displays NASDAQ KURA stock exchange data. View the KURA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Kura Oncology Inc real time stock price chart below.
What Is the Kura Oncology Inc Stock Price Today?
The Kura Oncology Inc stock price today is 9.05.
What Is the Stock Symbol for Kura Oncology Inc?
The stock ticker symbol for Kura Oncology Inc is KURA.
Is KURA the Same as $KURA?
$KURA is a common way to refer to the Kura Oncology Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Kura Oncology Inc Trade On?
Kura Oncology Inc is listed and trades on the NASDAQ stock exchange.
Is Kura Oncology Inc a Good Stock to Buy?
Determining whether Kura Oncology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Kura Oncology Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KURA quote. (ISIN: US50127T1097)
What Is the Kura Oncology Inc Stock Price Today?
The Kura Oncology Inc stock price today is 9.05.
What Is the Stock Symbol for Kura Oncology Inc?
The stock ticker symbol for Kura Oncology Inc is KURA.
Is KURA the Same as $KURA?
$KURA is a common way to refer to the Kura Oncology Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Kura Oncology Inc Trade On?
Kura Oncology Inc is listed and trades on the NASDAQ stock exchange.
Is Kura Oncology Inc a Good Stock to Buy?
Determining whether Kura Oncology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Kura Oncology Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KURA quote. (ISIN: US50127T1097)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.90
9.28
52 wk Range
5.45
12.49
Earnings results expected in 14 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.909.28
52 wk Range
5.4512.49
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KURA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
31.82
Upside
+251.58%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings downwards for the upcoming period
- Form DEF 14A KURA ONCOLOGY For: 10 April
- Investing.com
- Kura Oncology Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form DEF 14A KURA ONCOLOGY For: 10 April
- Investing.com
- Kura Oncology Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Kura Oncology Inc SWOT Analysis
Analyst Outlook | Price targets range from $11 to $40, averaging $25.38, reflecting confidence in Kura's oncology portfolio despite competitive challenges in the menin inhibitor space. |
Financial Strength | With $630.7 million cash runway into 2027 and expected milestone payments of $100-150 million, Kura positions itself for sustained growth despite projected EPS of -3.39 for FY1. |
Pipeline Expansion | Explore how Kura is leveraging its lead drug beyond initial approval, with promising combination therapies in first-line AML treatment and innovative trials for gastrointestinal tumors. |
FDA Milestone | Kura Oncology's recent FDA approval of Komzifti (ziftomenib) for NPM1-mutated AML marks its transition from clinical-stage to commercial biopharmaceutical company. |
Kura Oncology Inc Earnings Call Summary for Q4/2025
- Kura Oncology posted Q4 2025 EPS of -$0.92 vs. -$0.26 forecast; revenue of $17.34M missed $74.52M estimate by 76.73%, stock fell 4.21%.
- Net loss widened to $81M from $19.2M year-over-year due to increased R&D and SG&A expenses for AML programs and commercial infrastructure.
- Komzifti FDA approval marked transition to commercial-stage company, generating $2.1M in initial launch revenue during the quarter.
- Cash position of $667.2M provides runway through 2028; company expects significant revenue growth from AML programs despite near-term losses.
- Wall Street maintains Strong Buy rating with price targets of $16-$76; CEO Wilson emphasized long-term AML program potential despite financial challenges.
Last Updated: 03/05/2026, 08:54 AM
Read Full TranscriptCompare KURA to Peers and Sector
Metrics to compare | KURA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKURAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.9x | −2.5x | −0.5x | |
PEG Ratio | 0.05 | −0.19 | 0.00 | |
Price / Book | 4.6x | 4.9x | 2.6x | |
Price / LTM Sales | 11.9x | 118.0x | 3.2x | |
Upside (Analyst Target) | 208.7% | 92.5% | 45.7% | |
Fair Value Upside | Unlock | 2.7% | 4.8% | Unlock |
Analyst Ratings
13 Buy
1 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 31.82
(+251.58% Upside)
Earnings
Latest Release
Mar 05, 2026
EPS / Forecast
-0.92 / -0.26
Revenue / Forecast
17.34M / 74.52M
People Also Watch
FAQ
What Is the Kura Oncology Inc (KURA) Stock Price Today?
The Kura Oncology Inc stock price today is 9.05 USD.
What Stock Exchange Does Kura Oncology Inc Trade On?
Kura Oncology Inc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Kura Oncology Inc?
The stock symbol for Kura Oncology Inc is "KURA."
What Is the Kura Oncology Inc Market Cap?
As of today, Kura Oncology Inc market cap is 796.73M USD.
What Is Kura Oncology Inc's Earnings Per Share (TTM)?
The Kura Oncology Inc EPS (TTM) is -3.18.
When Is the Next Kura Oncology Inc Earnings Date?
Kura Oncology Inc will release its next earnings report on Apr 30, 2026.
From a Technical Analysis Perspective, Is KURA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Kura Oncology Inc Stock Split?
Kura Oncology Inc has split 0 times.
How Many Employees Does Kura Oncology Inc Have?
Kura Oncology Inc has 260 employees.
What is the current trading status of Kura Oncology Inc (KURA)?
As of Apr 16, 2026, Kura Oncology Inc (KURA) is trading at a price of 9.05 USD, with a previous close of 9.14 USD. The stock has fluctuated within a day range of 8.90 USD to 9.28 USD, while its 52-week range spans from 5.45 USD to 12.49 USD.
What Is Kura Oncology Inc (KURA) Price Target According to Analysts?
The average 12-month price target for Kura Oncology Inc is 31.82 USD, with a high estimate of 76 USD and a low estimate of 15 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +251.58% Upside potential.
What Is the KURA Premarket Price?
KURA's last pre-market stock price is 9.19 USD. The pre-market share volume is 760.00, and the stock has decreased by 0.05, or 0.55%.
What Is the KURA After Hours Price?
KURA's last after hours stock price is 9.12 USD, the stock has decreased by 0.05, or 0.55%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.